Cargando…
Low frequency vibrating magnetic field-triggered magnetic microspheres with a nanoflagellum-like surface for cancer therapy
BACKGROUND: The magneto-mechanical force killing cancer cells is an interesting and important strategy for cancer therapy. RESULTS: Novel magnetic microspheres composed of a Fe(3)O(4) nanocore, a bovine serum albumin (BSA) matrix, and a rod-like SiO(2) nanoshell, which had flagellum-like surface for...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258173/ https://www.ncbi.nlm.nih.gov/pubmed/35794559 http://dx.doi.org/10.1186/s12951-022-01521-7 |
Sumario: | BACKGROUND: The magneto-mechanical force killing cancer cells is an interesting and important strategy for cancer therapy. RESULTS: Novel magnetic microspheres composed of a Fe(3)O(4) nanocore, a bovine serum albumin (BSA) matrix, and a rod-like SiO(2) nanoshell, which had flagellum-like surface for force-mediated cancer therapy were developed. One such magnetic microsphere (Fe(3)O(4)/BSA/rSiO(2)) at a cancer cell (not leave the cell surface) under a low frequency vibrating magnetic field (VMF) could generate 6.17 pN force. Interestingly, this force could induce cancer cell to generate reactive oxygen species (ROS). The force and force-induced ROS could kill cancer cells. The cell killing efficiency of Fe(3)O(4)/BSA/rSiO(2) exposed to a VMF was enhanced with increasing silica nanorod length, and the microspheres with straight nanorods exhibited stronger cell killing ability than those with curled nanorods. Fe(3)O(4)/BSA/rSiO(2) triggered by a VMF could efficiently inhibit mouse tumor growth, while these microspheres without a VMF had no significant effect on the cell cycle distribution, cell viability, tumor growth, and mouse health. CONCLUSIONS: These microspheres with unique morphological characteristics under VMF have great potential that can provide a new platform for treating solid tumors at superficial positions whether with hypoxia regions or multidrug resistance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-022-01521-7. |
---|